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S_nmary The ability of the calcium antagonists, cinnarizine and flunarizine, to enhance the radiosensitis-
ation produced by the administration of an erythrocyte transfusion to anaemic, RIF-1 or SCCVII/St tumour
bearing mice was determined. Erythrocyte transfusion alone increased radiation cell killing 10-fold in the
RIF-1 tumour when given 0-4 h before X-rays. In contrast, the SCCVII/St showed only a 4-fold increase in
sensitivity, apparent when erythrocytes were given 2-6 h before irradiation. The administration of 50 mg kg-
cinnarizine or flunarizine to anaemic mice followed by erythrocyte transfusion 0 h before X-rays produced the
same level of cell survival for both tumours, a 20-fold increase in cell killing for cinnarizine, and a 30-40-fold
effect for flunarizine, even though at this time interval, the erythrocyte transfusion alone did not sensitise the
SCCVII St tumour to X-rays. Further investigations indicated, however, that the erythrocyte transfusion was
necessary to achieve the sensitisation with the calcium antagonists, since giving flunarizine to anaemic mice
alone only achieved a 4-fold increase in radiation cell killing. In addition, flunarizine given with erythrocyte
transfusion 4 h before X-rays, in SCCVII/St. the optimal time for radiosensitisation in this tumour, did not
further increase the level of cell killing achieved by flunarizine plus erythrocyte transfusion 0 h before X-rays.
The presence of hypoxic cells within a tumour will generally
lead to poor radiation response. Subpopulations of hypoxic
cells have now been described which are characterised by
their location within the tumour and by the mechanism by
which they become oxygen deprived. One subgroup, the
chronically hypoxic cells, are deprived of oxygen simply
because their location is remote from blood vessels, and their
oxygen supply may be described as diffusion limited. It
follows that any alteration in the oxygen carrying capacity of
the blood would affect the size of the chronically hypoxic
cell fraction and therefore tumour radiosensitivity. This has
been demonstrated by Hirst et al. (1984), where alterations
in host haematocrit had a large effect on tumour sensitivity
to X-rays. In particular, the use of an erythrocyte trans
fusion to restore the haematocrit of an anaemic, tumour
bearing mouse produced a large increase in radiation sensiti-
vity (Hirst & Wood, 1987).
A second subpopulation of hypoxic cells, first suggested
by Brown (1979) and recently demonstrated by Chaplin et al.,
(1986), arises when the blood supply to a tumour is reduced
due to blood vessel constriction. Such a phenomenon occurs
naturally, but nevertheless may lead to a temporary hypoxic
state for tumour cells located close to the blood vessels.
These cells may be described as acutely hypoxic, and the
oxygen supply is considered perfusion limited. This type of
hypoxic cell may therefore be targeted by agents which
increase tumour perfusion, such as some calcium antagonists.
Two of these agents, verapamil and flunarizine, have been
demonstrated to increase blood flow in experimental
tumours (Kaelin et al., 1982, 1984), and flunarizine has been
shown to be an efficient radiosensitiser in murine tumours
(Hill & Stirling, 1987; Wood & Hirst, 1988). If these two
distinct subpopulations of hypoxic cells are present in the
same tumour, then it follows that the combination of the
two manipulations described above to reduce these subpopu-
lations may enhance further the radiation sensitivity of the
tumour. The aim of this project was therefore to investigate
the radiosensitising capabilities of flunarizine and a related
compound, cinnarizine, in combination with erythrocyte
transfusion on the radiosensitivity of two murine tumours.
RIF-I and SCCVII/St, in anaemic mice.
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Materials and methods
Mice and tumour systems
The RIF-l sarcoma and the SCCVII St carcinoma were used
in the experiments. The protocol for the maintenance of
RIF-l has been described elsewhere (Twentyman et al., 1980)
and was also applied to SCCVII/St. Female C3H km mice at
12-14 weeks of age were inoculated intradermally on the
back with 2 x 105 cells in Waymouth's medium with 15%
foetal calf serum, to initiate tumour growth. Tumours were
randomly assigned to experimental groups 11-14 days later,
when tumours reached 200-600 mg in weight.
Calcium antagonists
Cinnarizine (l-(diphenylmethyl)-4-{3-phenyl-2-propenyl) pip-
erazine and flunarizine (1-bisf(4-fluorophenyl)methyl]-
4-(3-phenyl-2-propenyl) piperazine) were kindly supplied
by Janssen Pharmaceuticals, Beerse, Belgium. The com-
pounds were prepared for injection immediately before use
by suspending in peanut oil (Sigma Chemical Co., St Louis,
Mo). The agents were administered by intraperitoneal in-
jetion at a volume of 0.01 mlg - mouse weight.
Induction of anaemia and ervthrocvte transfusion
Haematocrits from all experimental mice were taken before
experiment, by removing 5 pi of blood from the tail vein into
a capillary tube. Samples were spun in a microhaematocnrt
centrifuge (Adam's Autocrit, New York) and the value read
from a microhaematocrit reader. Since normal mouse haem-
atocrit is 40-50%, mice with haematocrits below 40% were
excluded from the experiment. Mice were made anaemic by
collecting 0.5-0.7 ml of blood from the suborbital sinus,
under light ether anaesthesia, using a heparinised Pasteur
pipette. An equivalent volume of plasma was injected within
10 mmn of bleeding to restore blood volume. The plasma was
prepared from the pooled blood of syngeneic donors. Haem-
atocnts were taken, and those below 30% were considered
acceptable. The haematocrit was restored 24 h after anaemia
by giving a tail vein injection of 0.5-0.7 ml of packed
erythrocytes, again prepared from the pooled blood of
syngeneic donors, and used within 6 h of removal from the
donor animal. Haematocnrts were determined again, and
values over 40% were accepted.
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Irradiation and assay for tumour response
Mice were given a 20 Gy whole body dose of 250 kVp X-
rays at a dose rate of 2.85 Gy min' while breathing a
normal atmosphere.
Tumour radiosensitivity was measured by the in vivo/in
vitro assay. Mice were killed by cervical dislocation 18-24 h
after irradiation. The tumour was excised, weighed and
finely chopped with scissors. A single cell suspension was
prepared from the chopped tumour as described previously
(Hirst et al., 1982). Haemacytometer determinations of cell
concentration were made, the cell suspension was appro-
priately diluted and plated at the required concentration in
plastic tissue culture dishes (Becton Dickinson Labware,
Oxnard, CA), in Waymouth's medium with 15% fetal calf
serum. Cells were plated at two concentrations with three
dishes per concentration for each data point. Dishes were
incubated for 12-14 days at 37°C in humidified 5% CO in
air. Colonies with more than 50 cells were scored after
staining with crystal violet stain. Plating efficiency and
surviving fraction were calculated from colony counts.
Results
The time course for the effect of anaemia and erythrocyte
transfusion on tumour radiation response has been reported
in full elsewhere (Hirst & Wood, 1987). The induction of
anaemia in both the RIF-I and the SCCVII/St tumours
increased tumour radioresistance to 20 Gy X-rays, up to 6 h
before irradiation, but the effect was lost by 24 h, although
the anaemia was still maintained at this time. The erythro-
cyte transfusion for this series of experiments was therefore
given 24 h after the induction of anaemia.
The time course for the effect of erythrocyte transfusion
on tumour response to 20 Gy X-rays in anaemic mice has
been reproduced in Figure la for the RIF-I tumour, and
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Figure lb for SCCVII/St These data have been published
elsewhere (Wood & Hirst, 1988) and are reproduced with
permission. In both cases radiosensitisation occurred, but the
time course and the size of the effect were different for the
two tumours. In RIF-I there was a 5-10-fold increase in cell
killing when transfusion was given 0-6h before irradiation,
but this effect was gradually lost over the next 24-48 h. In
the SCCVII/St tumour, however, maximal sensitisation was
not seen until the erythrocyte transfusion had been given 2-6
h before irradiation, with only a 4-6-fold increase in cell
killing. In this case, the effect was lost by 12 h.
The effects of cinnarizine and flunarizine on the radio-
sensitisation produced by the above manipulation were then
determined. Cinnariine or flunarizine were given by i.p.
injection at a dose of 50 mg kg- I to anaemic, tumour
bearing mice at varying time intervals before 20 Gy X-rays.
An erythrocyte transfusion was then given immediately
before irradiation. It is important to note that this time
interval was used in the SCCVII/St tumour as well as in
RIF-1, although it was not the optimal time for radio-
sensitisation. Figure 2 gives the results for the effect of
cinnarizine plus erythrocyte transfusion on tumour radio-
sensitivity in a, RIF-I and b, SCCVII/St tumours. Cinnari-
zine enhanced the transfusion induced radiosensitisation in
both tumours, with a maximal effect at 3 h before irradia-
tion. The combined treatments enhanced radiation cell kill-
ing 20-fold. Similar results were obtained for flunarizine,
given in Figure 3a for RIF-I and Figure 3b for SCCVII/St,
where a maximal 30-fold increase in cell killing was achieved
at 3-4 h before X-rays. The injection vehicle, peanut oil, was
determined to have no effect on tumour radiosensitivity
under these experimental conditions.
The observation that the combined treatments produced
similar reductions in cell survival in both tumours, even
though the erythrocyte transfusion alone appeared not to
affect radiosensitivity in the SCCVII/St tumour, led to two
further investigations. Firstly, it was determined whether the
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Fngwe 1 Tune course for the effect oferythrocyte transfusion on the sensitivity of(a) RIF-I and (b) SCCVII/St tumours to20OGy
X-rays in ana mic e. 0, anaemic mice; 0, anac mice receiving erytrocyte transfusion before irradiation. Points are
geometnc means+s.e. from three experiments, three mice per data point. Cross-hatching gives response to 20Gy X-rays in normal
mice.
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Fugwe 2 Time course of the effect of 50mg kg-1 cinnarizine on the sensitivity of (a) RIF-I and (b) SCCVII/St tumours to
20Gy X-rays in anaemic mice receiving erythrocyte transfusion immediately before irradiation. 0, effect of erythrocyte trans-
fusion alone; *, effect of50mg kg cinnarizinepluserythrocyte transfusion. Points aregeometric means+ s.e. from threeexperiments,
three mice per data point. Cross-hatching gives response to 20Gy X-rays in normal mice.
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Figwe 3 Time course of the effect of 50mgkg - flunarizine on the sensitivity of (a) RIF-I and (b) SCCVII/St tumours to
20Gy X-rays in anaemic mice receiving erythrocyte transfusion immediately before irradiation. 0, effect of erythrocyte trans-
fusion alone; 0, effect of50 mgkg- flunarizine pluserythrocyte transfusion. Points aregeometric means + s.e. from threeexperiments,
three mice per data point Cross-hatching gives response to 20Gy X-rays in normal mice.
erythrocyte transfusion was actually necessary to achieve the
observed level of cell killing in SCCVII/St. Flunarizine at 50
mg kg-
' was given to anaemic, tumour bearing mice at
various time intervals before 20 Gy X-rays, but with no
erythrocyte transfusion. The results are given in Figure 4.
Clearly the increase in cell killing was not of the magnitude
seen when the erythrocyte transfusion was also given.
Secondly, since the maximal effect of the erythrocyte trans-
fusion in SCCVH/St was actually seen 4-6 h before X-rays,
it was also determined whether using this time interval for
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Fugwe 4 Time course for the effect of 50 mg kg-l flunarize
on the sensitivity of the SCCVII/St tumour to 20 Gy X-rays in
anaenic mice. Points are geometrc means +s.e. from two
experiments, three mice per data point. Cross-hatching gives
response to 2OGy X-rays in normal mice.
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Figwe 5 Time course for the effect of 50 mg kg-' flunariine
on the sensitivity of the SCCVII/St tumour to 20 Gy X-rays in
anaemic mice recevmg erythrocyte transfusion 4 h before irra-
diation. 0, effect of erythrocyte transfusion alone; 0* effect of
50mgkg- flunarizine plus erythrocyte transfusion. Points
are geometnc means+s.e. from two experiments, three mice per
data point. Cross-hatching gives response to 20Gy X-rays in
normal mice.
the transfusion improved the radiosensitisation for the com-
bination of treatments over that seen when transfusion was
immediately before X-rays. Flunarizine at 50 mg kg-' was
given to anaemic, SCCVH/St tumour bearing mice at various
times before 20 Gy X-rays, with the erythrocyte transfusion
given 4 h before irradiation. The results are given in Figure
5. The administration of flunarizine 0-4 h before X-rays did
not significantly enhance the effect of the erythrocyte trans-
fusion in the SCCVII/St tumour given 4 h before irradiation,
and neither was there any increase m tumour radiosensitis-
ation for this combination of treatments over than when
transfusion was immediately before X-rays.
Discession
In combination with erythrocyte transfusion, flunarizine is
marginally better at sensitising both tumours to X-rays than
cinnarizine. The effect is not so pronounced as that reported
for the cinnarizine and flunarizine radiosensitisation in
normal mice (Wood & Hirst, 1988). The reason for this is
not clear but may be related to the fact that in this study
cinnarizine and flunarizine are being given to anaemic mice.
The data in Figure 4 support this, since flunarizine induces
only a 3-fold increase in cell killing at 4 h before X-rays,
compared with a 10-fold sensitisation at 45 min before
irradiation in normal mice (Wood & Hirst, 1988).
Of particular interest is that for a given calcium antago-
nist, there is no difference in the response to the combination
treatment between the two tumours. This is in contrast to
the effects of the calcium antagonists alone where the
response of the RIF-I tumour was much less than that of
SCCVII/St (Wood & Hirst, 1988). It was suggested that the
reason for this difference was the presence of a subpopula-
tion of hypoxic cells in SCCVII/St which were targeted by
the calcium antagonists, and which were absent from the
RIF-l tumour. In this study, the transfusion of erythrocytes
to anaemic mice immediately before X-rays produced a
better sensitisation in the RIF-I tumour than in SCCVII/St.
It could be argued therefore that this treatment is targeting
another subpopulation of hypoxic cells, which exist in
greater numbers in the RIF-I tumour than in SCCVII/St. It
follows from these two assumptions that the combination of
calcium antagonists and erythrocyte transfusion would be
expected to result in the same level of cell killing in both
tumours. These results at first do not appear to agree with
the findings of Hill & Stirling (1987), who demonstrated that
flunarizine did not enhance the radiosensitisation of the
KHT tumour by erythrocyte transfusion to anaemic mice.
However, the reason given was that the KHT tumour has
poorly formed blood vessels and therefore may not have
acutely hypoxic cells. It follows then, that flunarizine may
not be expected to enhance the effects of erythrocyte trans-
fusion in this tumour.
However, it is important to note that the administration of
the erythrocyte transfusion immediately before X-rays in the
SCCVII/St tumour does not in itself produce radiosensitis-
ation, and that it appears to take at least 4 h for the effect
to become apparent. This phenomenon was first noted by
Hirst & Wood (1987) and it was suggested that the vascula-
ture of the SCCVII/St tumour required some time to
accommodate the increased viscosity of the blood after the
erythrocyte transfusion. If this is so, the first question to
arise is whether the erythrocyte transfusion just before
irradiation is necessary for the level of sensitisation seen,
since the calcium antagonists are actually being given to
anaemic mice. Figure 4 indicates that the erythrocyte trans-
fusion immediately before irradiation is indeed necessary.
This may be expected, if the modes of action of cinnarizine
and flunarizne are considered. These agents are thought to
act in two ways, by preventing the naturally occurring
constriction of small vessels in or around the tumour, which
produce acute hypoxia within the tumour (Chaplin et al.,
1986) and by preventing the hypoxia induced rigidification of
blood celular components (DeCree et al., 1979; also see
Jirtle, 1988 for review). In this particular case, the mainten-
ance of patent capillaries by the calcium antagonist would
facilitate the passage of the transfused erythrocytes given
immediately before X-rays, allowing the contribution of the
latter to the overall sensitisation. Reduction in erythrocyte
rigidity by the calcium antagonists may also contribute to
the effect of the erythrocyte transfusion on radiosensitisation
by improving the passage of the transfused red cells through
smaller blood vessels and increasing tumour oxygenation.
The second question is then, if the optimal time for sensitisa-
tion byerythrocyte transfusion alone in the SCCVII/St tumour
is 4-6 h before irradiation, does administration ofthe erythro-
cytes at this time, in combination with the calcium antago-
nists improve on the radiosensitisation seen with transfusion
immediately prior to X-rays? The answer given in Figure 5 is
that it does not. This may be expected, since maximal
radiosensitisation by the erythrocyte transfusion at this time
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interval suggests that the transfused red cells have reached
their optimal state of oxygenation, and that the tumour has
adapted to the increased viscosity produced by the additional
red cells. Thus the administration of flunarizine at the same
time as or after the erythrocyte transfusion may not be
expected to improve on the radiosensitising ability of the
transfusion itself. The cell survival levels for the admini-
stration of flunarizine 4 h before X-rays, whether transfusion
is given 0 h or 4 h before irradiation, are not significantly
different (P>0.1). However, it may be of interest to deter-
mine whether giving flunarizine at even earlier times before
the erythrocyte transfusion, that is more than 4 h before X-
rays, can improve further the radiosensitisation by the
combination treatment.-This may be possible, since Figure 4
suggests that the administration of flunarizine to anaemic
mice appears to increase the optimal time of radiosensitis-
ation to at least 4 h.
The results presented indicate that some extra benefit in
X-ray sensitivity may be obtained by combining methods of
increasing oxygen delivery to tumours, when the methods
target different types of hypoxic cell. In the case of the
SCCVII/St tumour, the combined radiosensitisation may be
alternatively described as an improvement in the effects of
the erythrocyte transfusion by the calcium antagonists, in
addition to the direct effects of the agents themselves.
In terms of the clinical relevance of the results presented,
there is no doubt that this type of treatment combination
can greatly improve radiation sensitivity. For example, the
administration of a blood transfusion to previously anaemic
cancer patients may have some benefit, indicated in clinical
trials for cancer of the cervix and head and neck (Bush et
al., 1978; Overgaard et al., 1986). However, the recent
concern over contamination of blood products suggests that
the search for an alternative to this method of tumour
oxygenation would be advantageous. These may include the
use of hyperbaric oxygen or carbogen, where the increased
tumour perfusion induced by the calcium antagonists would
complement the increased oxygen carrying capacity of the
blood. The adminstration of perfluorocarbons with calcium
antagonists may be a promising combination, again with the
improved tumour perfusion allowing further passage of the
oxygen carrying perfluorocarbon molecules to remote tissues.
Finally, the use of agents which reduce haemoglobin affinity
for oxygen, such as the antilipidaemic agents, clofibrate and
bezafibrate have been shown to increase tumour radio-
sensitivity (Hirst & Wood, 1988a) and might be expected to
target the diffusion limited hypoxic cells within the tumour.
These agents may therefore be expected to increase tumour
radiosensitivity with calcium antagonists. However, prelimi-
nary experiments with clofibrate and flunarizine in this
laboratory produce a less than additive radiosensitisation,
which may be due to clofibrate also exhibiting the ability to
increase tumour perfusion (Hirst & Wood, 1988b).
In conclusion, the use of the calcium antagonists cinnanr-
zine and flunarizine to improve the radiosensitising ability of
erythrocyte transfusion to anaemic mice is demonstrated,
and although blood transfusion is not considered a treatment
of choice as an adjuvant to radiotherapy, the calcium
antagonists may have a future in combination with other,
established methods of altering tumour oxygen delivery.
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